TY - JOUR
T1 - Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy
AU - Mhawech-Fauceglia, Paulette
AU - Wang, Dan
AU - Samrao, Damanzoopinder
AU - Kim, Grace
AU - Lawrenson, Kate
AU - Meneses, Teodulo
AU - Liu, Song
AU - Yessaian, Annie
AU - Pejovic, Tanja
PY - 2014/8
Y1 - 2014/8
N2 - Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.
AB - Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.
KW - Cancer-associated fibroblasts (CAF)
KW - Disease outcome
KW - Epithelial ovarian cancer (EOC)
KW - Neoadjuvant therapy
UR - http://www.scopus.com/inward/record.url?scp=84907018262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907018262&partnerID=8YFLogxK
U2 - 10.1007/s12307-013-0140-4
DO - 10.1007/s12307-013-0140-4
M3 - Article
AN - SCOPUS:84907018262
SN - 1875-2292
VL - 7
SP - 33
EP - 39
JO - Cancer Microenvironment
JF - Cancer Microenvironment
IS - 1-2
ER -